Enovis Management

Management Kriterienprüfungen 3/4

Enovis CEO ist Matt Trerotola , ernannt in Jul 2015, hat eine Amtszeit von 9.33 Jahren. Die jährliche Gesamtvergütung beträgt $10.77M , bestehend aus 10% Gehalt und 90% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.32% der Aktien des Unternehmens, im Wert von $8.27M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.8 Jahre bzw. 4.3 Jahre.

Wichtige Informationen

Matt Trerotola

Geschäftsführender

US$10.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	10.0%
Amtszeit als Geschäftsführer	9.3yrs
Eigentum des Geschäftsführers	0.3%
Durchschnittliche Amtszeit des Managements	5.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.3yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Matt Trerotola im Vergleich zu den Einnahmen von Enovis verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 27 2024	n/a	n/a	-US$121m
Jun 28 2024	n/a	n/a	-US$107m
Mar 29 2024	n/a	n/a	-US$103m
Dec 31 2023	US$11m	US$1m	-US$54m
Sep 29 2023	n/a	n/a	-US$112m
Jun 30 2023	n/a	n/a	-US$159m
Mar 31 2023	n/a	n/a	-US$23m
Dec 31 2022	US$12m	US$1m	-US$39m
Sep 30 2022	n/a	n/a	US$1m
Jul 01 2022	n/a	n/a	US$54m
Apr 01 2022	n/a	n/a	-US$109m
Dec 31 2021	US$14m	US$1m	-US$103m
Oct 01 2021	n/a	n/a	-US$48m
Jul 02 2021	n/a	n/a	-US$18m
Apr 02 2021	n/a	n/a	US$21m
Dec 31 2020	US$8m	US$1m	-US$75m
Oct 02 2020	n/a	n/a	US$53m
Jul 03 2020	n/a	n/a	US$39m
Apr 03 2020	n/a	n/a	US$42m
Dec 31 2019	US$8m	US$1m	US$8m
Sep 27 2019	n/a	n/a	US$10m
Jun 28 2019	n/a	n/a	US$21m
Mar 29 2019	n/a	n/a	US$66m
Dec 31 2018	US$3m	US$1m	US$108m
Sep 28 2018	n/a	n/a	-US$115m
Jun 29 2018	n/a	n/a	-US$84m
Mar 30 2018	n/a	n/a	-US$92m
Dec 31 2017	US$3m	US$1m	US$28m

Vergütung im Vergleich zum Markt: MattDie Gesamtvergütung ($USD10.77M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD2.76M).

Entschädigung vs. Einkommen: MattDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Matt Trerotola (57 yo)

9.3yrs

Amtszeit

US$10,774,635

Vergütung

Mr. Matthew L. Trerotola, also known as Matt, has been the Chief Executive Officer of Enovis Corporation (formerly known as Colfax Corporation) since July 24, 2015 and had been its President from July 2015...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Matthew Trerotola	CEO & Chairman	9.3yrs	US$10.77m	0.32% $ 8.3m
Phillip Berry	Senior VP & CFO	1.8yrs	US$2.36m	0.063% $ 1.6m
Patricia Lang	Senior VP & Chief Human Resources Officer	5.8yrs	US$2.07m	0.040% $ 1.0m
Daniel Pryor	Executive Vice President of Strategy & Business Development	11.3yrs	US$4.75m	0.15% $ 4.0m
Brady Shirley	Executive Advisor & Director	8yrs	US$5.20m	0.11% $ 2.8m
John Kleckner	VP, Controller & Chief Accounting Officer	2.5yrs	keine Daten	0.012% $ 299.3k
Derek Leckow	Vice President of Investor Relations	no data	keine Daten	keine Daten
Bradley Tandy	Senior VP & Chief Legal Officer	5.8yrs	keine Daten	0.045% $ 1.2m
Katie Sweet	Vice President of Corporate Communication	no data	keine Daten	keine Daten
Tim Czartoski	President of U.S. Surgical and Global Product & Enabling Technologies	less than a year	keine Daten	keine Daten
Terry Ross	Group President Prevention & Recovery	no data	keine Daten	0.035% $ 908.1k
Brian Hanigan	Secretary	no data	keine Daten	keine Daten

5.8yrs

Durchschnittliche Betriebszugehörigkeit

56.5yo

Durchschnittliches Alter

Erfahrenes Management: 0I1BDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Matthew Trerotola	CEO & Chairman	9.3yrs	US$10.77m	0.32% $ 8.3m
Brady Shirley	Executive Advisor & Director	2.6yrs	US$5.20m	0.11% $ 2.8m
Sharon Wienbar	Lead Independent Director	8.4yrs	US$316.46k	0% $ 0
A. Perfall	Independent Director	14.2yrs	US$308.93k	0.0044% $ 114.5k
Angela Lalor	Independent Director	2.6yrs	US$296.46k	0.022% $ 560.3k
Rajiv Vinnakota	Independent Director	16.5yrs	US$298.93k	0.039% $ 1.0m
Liam Kelly	Independent Director	4.8yrs	US$283.93k	0.023% $ 600.6k
Philip Okala	Independent Director	3.8yrs	US$283.93k	0.015% $ 381.3k
Barbara Bodem	Independent Director	2.6yrs	US$283.93k	0.015% $ 381.3k
Christine Ortiz	Independent Director	2.6yrs	US$283.93k	0.015% $ 381.3k

4.3yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrener Vorstand: 0I1BDie Vorstandsmitglieder gelten als erfahren (4.3 Jahre durchschnittliche Amtszeit).

Enovis Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Enovis Corp Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

Enovis Corporation, Annual General Meeting, May 20, 2024

Enovis Corporation Announces Leadership Transition Plan

High number of new directors

High number of new directors

High number of new directors

Recent updates

Third quarter 2024 earnings released: US$0.62 loss per share (vs US$0.36 loss in 3Q 2023)

Enovis Corporation Narrows Earnings Guidance for the Year 2024

Enovis Corporation to Report Q3, 2024 Results on Nov 06, 2024

Enovis Corp Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

Enovis Continues to Redefine Revision Knee Surgery with the Addition of Emowr Revision Knee

Enovis Corporation Introduces Star Ankle, Now with E+ Polyethylene for Unmatched Durability

Second quarter 2024 earnings released: US$0.34 loss per share (vs US$0.27 loss in 2Q 2023)

Enovis Corporation Narrows Revenue Guidance for the Year 2024

Enovis Corporation to Report Q2, 2024 Results on Aug 07, 2024

Enovis Releases AltiVate Reverse Glenoid System, Widening Range of Patients Who May Be Treated with AltiVate Reverse

Enovis Corporation Updates Earnings Guidance for the Year 2024

Enovis Corporation to Report Q1, 2024 Results on May 02, 2024

Enovis Corporation, Annual General Meeting, May 20, 2024

Full year 2023 earnings released: US$0.99 loss per share (vs US$0.72 loss in FY 2022)

New major risk - Revenue and earnings growth

Enovis Corporation Provides Earnings Guidance for the Year 2024

Enovis Corporation to Report Q4, 2023 Results on Feb 22, 2024

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

Enovis Corporation Announces Leadership Transition Plan

No longer forecast to breakeven

Third quarter 2023 earnings released: US$0.36 loss per share (vs US$1.22 loss in 3Q 2022)

Enovis Corporation to Report Q3, 2023 Results on Nov 07, 2023

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

High number of new directors

Enovis Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.26 loss per share (vs US$2.23 profit in 2Q 2022)

Enovis Corporation to Report Q2, 2023 Results on Aug 03, 2023

High number of new directors

Enovis Corporation (NYSE:ENOV) acquired Novastep Inc. from Amplitude Surgical SA (ENXTPA:AMPLI).

High number of new directors

High number of new directors

Enovis Corporation Revises Earnings Guidance for the Year 2023

Enovis Corporation to Report Q4, 2022 Results on Feb 23, 2023

Enovis Corporation Announces the Launch of the Dynaclip Delta and Dynaclip Quattro Bone Staples

Enovis Receives FDA Approval of Patient Specific Instrumentation for STAR Ankle

Enovis Corporation Announces Introduction of DynaNail Helix

Third quarter 2022 earnings released: US$1.22 loss per share (vs US$0.26 loss in 3Q 2021)

Enovis Corporation Provides Earnings Guidance for the Year 2022

High number of new directors

Enovis Corporation to Report Q3, 2022 Results on Nov 02, 2022

High number of new directors

Enovis Launches ARVIS®, Only Augmented Reality Surgical Guidance System Designed Specifically to Improve Both Total Hip and Knee Replacement Surgery

Enovis Corporation to Report Q2, 2022 Results on Aug 04, 2022

Enovis Corporation (NYSE:ENOV) acquired Insight Medical Systems, Inc.

Enovis Corporation Announces That Ben Berry, CFO of the Company's Business Units, Will Succeed Chris Hix as Chief Financial Officer, Effective January 1, 2023

Enovis Corporation Launches Arsenal Ankle Plating System

Enovis Corporation Reaffirms Revenue Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$0.34 (vs US$0.57 in 1Q 2021)

High number of new directors

Enovis Corporation to Report Q1, 2022 Results on May 10, 2022

Enovis Corporation Announces Board Changes

Enovis Corporation completed the Spin-Off of ESAB Corporation (NYSE:ESAB).

Colfax Corporation Announces Board Resignations, Effective Upon the Consummation of the Separation of its Fabrication Technology Business

Executive VP of Finance & CFO recently sold US$71k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Colfax Corporation Provides Earnings Guidance for the Year 2022

Colfax Corporation Announces Management Changes, Effective May 13, 2022

Third quarter 2021 earnings released: EPS US$0.17 (vs US$0.12 in 3Q 2020)

Independent Director recently sold US$103k worth of stock

Co-Founder & Chairman of the Board recently bought US$12m worth of stock

Second quarter 2021 earnings released: EPS US$0.20 (vs US$0.026 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.19 (vs US$0.057 in 1Q 2020)

Colfax Corporation has completed a Follow-on Equity Offering in the amount of $644 million.

Colfax Corporation Announces Executive Changes for Two Differentiated, Independent, and Publicly-Traded Companies

Colfax Corporation Appoints Philip Okala to its Board of Directors

Full year 2020 earnings released: EPS US$0.44 (vs US$0.062 in FY 2019)

Revenue beats expectations

Colfax Corporation to Report Q4, 2020 Results on Feb 18, 2021